Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Novel UHPLC-MS/MS Based Bioanalytical Method Used for S-Allyl Cysteine Comparative Pharmacokinetic Study

Niyaz Ahmad
* ,
Mohd Faiyaz Khan
,
Faisal K Alkholifi
ORCID logo ,
Zabih Ullah
,
Sadaf Farooqui
,
Dr. Nazia Khan
,
Mohammed Saifuddin Khalid
,
Mir Naiman Ali
ORCID logo ,
Hajera Tabassum
ORCID logo
Version 1 : Received: 12 June 2023 / Approved: 12 June 2023 / Online: 12 June 2023 (14:09:39 CEST)

A peer-reviewed article of this Preprint also exists.

Khan, M.F.; Ahmad, N.; Alkholifi, F.K.; Ullah, Z.; Farooqui, S.; Khan, N.; Khalid, M.S.; Ali, M.N.; Tabassum, H. A Novel UHPLC-MS/MS-Based Bioanalytical Method Developed for S-Allyl Cysteine in the Establishment of a Comparative Pharmacokinetic Study. Separations 2023, 10, 423. Khan, M.F.; Ahmad, N.; Alkholifi, F.K.; Ullah, Z.; Farooqui, S.; Khan, N.; Khalid, M.S.; Ali, M.N.; Tabassum, H. A Novel UHPLC-MS/MS-Based Bioanalytical Method Developed for S-Allyl Cysteine in the Establishment of a Comparative Pharmacokinetic Study. Separations 2023, 10, 423.

Abstract

A newly UHPLC-MS/MS method development and validation for S-Allyl Cysteine was used to evaluate the comparative pharmacokinetic parameters. SC PLGA NPs were developed by the emulsion solvent evaporation method. SC PLGA NPs showed their drug loading and encapsulation efficiency i.e. 5.13±0.10% and 82.36±4.01%, respectively. SC PLGA NPs showed a spherical morphology on an average size (134.8±4.61nm), PDI: 0.277±0.004, and −25.3±1.03mV zeta-potential is suitable for oral delivery. Development and validation of the UHPLC-MS/MS bioanalytical method were performed successfully for PK-parameters examinations with 1.219-minutes RT, MS (162.00/73.10), and a total run-time was 2.0-minutes. 1.0–1000.0ng/mL was a linear-range with inter & intra-day accuracy (92.55–99.40%) followed by precision (1.88–4.23%). SC PLGA NPs oral bioavailability was significantly higher (**p<0.01) as compared to SC-S treated groups (iv & oral). We found that the antimicrobial activity of SC PLGA NPs was more effective than pure S-Allyl-L-Cysteine with significant results (p<0.01) as compared to SC-S. SC PLGA NPs showed fitted physicochemical and enhanced antimicrobial properties which can be helpful for oral administration. On the basis of our observations, SC PLGA NPs suggested the highest potential for the improvement of oral bioavailability with a sustained and controlled release of S-Allyl-L-Cysteine delivery.

Keywords

S-Allyl Cysteine; Oral Bioavailability; PLGA NPs; LC–MS/MS; Pharmacokinetics

Subject

Medicine and Pharmacology, Pharmacy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.